We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Fast, Accurate Test Aids in Detection of Lynch Syndrome

By LabMedica International staff writers
Posted on 04 Apr 2023

Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally, with around 3-5% of cases attributed to Lynch syndrome - an uncommon hereditary cancer predisposition syndrome that elevates the risk of developing CRC. More...

The current guidelines for cancer treatment emphasize the significance of testing for Mismatch Repair (MMR) status in all newly diagnosed CRCs as an initial screening procedure for Lynch syndrome. Immunohistochemistry (IHC), an increasingly prevalent clinical practice, is one of the suggested methods of testing.

Leica Biosystems’ (Nussloch, Germany) US FDA-cleared BOND MMR Antibody Panel now offers a high-performing IHC MMR option when screening CRC patients for identifying probable Lynch syndrome. The BOND MMR Antibody Panel is now available for clinical use on the BOND-III and BOND-MAX IHC automated instruments.

"Pathologists can utilize the Leica Biosystems BOND MMR Antibody Panel on the BOND-III for clear, accurate assessment of mismatch repair protein status in only 2.5 hours," said Dr. Robert Monroe, Chief Medical Officer at Leica Biosystems. "With this panel, clinicians can feel increased confidence in their MMR results."

"Leica Biosystems is proud to help our customers continue the fight against cancer through the fast, accurate results of the BOND MMR Antibody Panel, which provides the clinicians an important piece of the diagnostic puzzle in aiding the detection of Lynch syndrome," added Gustavo Perez-Fernandez, President of Leica Biosystems. "Our test enables targeted treatment for patients, supporting our mission of Advancing Cancer Diagnostics, Improving Lives."

Related Links:
Leica Biosystems


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
New
Uric Acid Meter
PA-16
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.